|Bid||37.10 x 1000|
|Ask||37.12 x 1200|
|Day's Range||37.04 - 37.53|
|52 Week Range||34.51 - 48.98|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||1.34|
|Expense Ratio (net)||0.35%|
U.S. stocks swung into negative territory, ending Tuesday’s session lower after a closely watched portion of the Treasury yield curve inverted further and stoked fears of a recession.
Institutional investors and hedge funds have shifted away from technology names as the U.S.-China trade war extends and picked up battered healthcare names. Retail investors can also gain exposure to the ...
Pharmaceutical ETFs invest in stocks of companies that are involved in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. With Johnson and Johnson continuing ...
Shares of health companies were down Monday, with both the Health Care Select Sector SPDR Fund ETF and the SPDR S&P Pharmaceuticals ETF falling 0.6% in morning intraday trade. Shares of Cardinal Health Inc. led the losers in the S&P 500's health-care ETF, falling 3.1% after the company said CFO Jorge Gomez would leaving the company, followed by declines in shares of Incyte Corp , Alexion Pharmaceuticals Inc. , and Biogen Inc. , Regeneron Pharmaceuticals Inc. and Amgen Inc. . The dip in health-care stocks comes after President Trump's announcement Friday that he was planning to soon issue an executive order allowing the U.S. to buy drugs based on the lowest price paid by other developed countries. "Our guess is drug stocks may be initially pressured this week," Jefferies health-care trading desk strategist Jared Holz wrote in an email to clients on Sunday evening. However, "feedback already suggests investors believe the executive order, if it comes to pass, will only be relevant for a handful of drugs (those that are very significant in revenue and administered in a physician's office)... at least at the onset," he wrote. The drop in health shares comes amid a broader decline in U.S. stocks, as investors grapple with doubts about whether the Federal Reserve will still cut interest rates after a strong U.S. jobs report Friday. The S&P 500 was down 0.4% Monday morning. The index has gained 18.8% in the year to date.
President Donald Trump on Friday applied fresh pressure on the Federal Reserve over interest-rate policy, and told reporters he was considering an executive order over a citizenship question on the 2020 census.
Pharmaceutical sector-specific exchange traded funds showed mixed results Tuesday after AbbVie (NYSE: ABBV) agreed to acquire Allergan (NYSE: AGN) for $63 billion. Among the largest pharma-specific ETFs, ...
Shares of drug makers were getting a nice boost in premarket trading Tuesday, after AbbVie Inc.'s deal to buy Allergan PLC for a 45% premium. The SPDR S&P Pharmaceuticals ETF rallied 2.2% ahead of the open. Besides the 31% jump in Allergan's stock, among other shares seeing nice gains in the premarket, Mylan N.V. rose 2.7%, Endo International PLC climbed 4.5%, Theravance Biopharma Inc. hiked up 4.2%, Mallinckrodt PLC tacked on 2.7% and Perrigo Co. PLC gained 2.2%. Meanwhile, Medicines Co.'s stock shed 4.6%, after the company announced late Monday the public offering of $150 million worth of common stock. The pharmaceuticals ETF has lost 7.7% over the past three months through Monday, while the S&P 500 has gained 5.3%.
Pharmaceutical ETFs may be in trouble with legal troubles looming over the industry. The drugmaker segment recently sold-off after an amended civil antitrust complaint brought by more than 40 state attorneys ...
The healthcare sector, the second-largest sector by exposure in the S&P 500, is in the midst of a dismal run. After ranking as the best-performing sector in the U.S. last year, healthcare is the worst-performing group in the S&P 500 in 2019.Just look at the Health Care Select Sector SPDR (NYSEARCA:XLV), the largest of healthcare ETFs by assets. XLV is down 0.84% year-to-date while the S&P 500 is higher by nearly 16%. XLV's year-to-date loss does not paint a complete picture of healthcare stocks' weakness. Investors' distaste for the sector has recently been increasing as highlighted by an April loss of more than 7% for XLV.While the long-term outlook for the healthcare sector remains solid, healthcare ETFs and stocks face myriad headwinds, including some that are politically-charged. As has been widely noted, the idea of Medicare For All has significant traction among several Democrats running for that party's 2020 presidential nomination and that is plaguing insurance providers and some more focused healthcare ETFs.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMore recently, politicians from both parties continued assailing high pharmaceuticals prices, sending the S&P Pharmaceuticals Select Industry Index lower by more than 6% for the week ending April 18. * 10 High-Yielding Dividend Stocks That Won't Wilt In other words, healthcare ETFs face a lot of near-term headwinds, meaning it could be time to consider dumping these funds. SPDR S&P Pharmaceuticals ETF (XPH)Source: Shutterstock Expense ratio: 0.35% per year, or $35 on a $10,000 investment.The SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) tracks the aforementioned S&P Pharmaceuticals Select Industry Index and even with the recent consternation over high drug prices, this healthcare ETF is maintaining a year-to-date gain of over 6%. That makes XPH one of the better-performing healthcare ETFs this year.The White House claims that it has affected favorable changes when it comes to drug prices, but with a presidential election year looming, the rhetoric on this issue is likely to increase, not abate, and that presents a potential headwind for a slew of healthcare ETFs, including XPH."Even if politicians truly wanted to lower drug prices, one complexity is that Medicare, which many candidates want to expand broadly, has no authority to negotiate thanks to a possibly ill-advised policy proposed by the Bush administration that has been in effect since 2006," according to CNBC.XPH and several other healthcare ETFs are front-and-center in the drug price debate. XPH's deteriorating technical health is another cause for concern with this healthcare ETF as the fund currently resides more than 10% below its 200-day moving average, a percentage that has recently been growing. Invesco S&P SmallCap Health Care ETF (PSCH)Source: Shutterstock Expense ratio: 0.29%The combination of small-cap stocks and the healthcare sector can be rewarding for investors when both of those elements are moving higher in unison. Small caps are doing their jobs this year, but healthcare is not, and that drag has recently been weighing on the Invesco S&P SmallCap Health Care ETF(NASDAQ:PSCH).PSCH, the small-cap counterpart to the aforementioned XLV, is a diversified healthcare ETF and its 69 holdings "are healthcare companies principally engaged in the business of providing healthcare-related products, facilities and services, including biotechnology, pharmaceuticals, medical technology and supplies," according to Invesco. * 7 Digital Ad Stocks That Deserve Your Attention Right Now In more sanguine environments for the healthcare sector, PSCH's diverse roster would be an advantage. For the time being, the opposite is true. PSCH's nearly 13% weight to pharmaceuticals stocks is a problem in its own right thanks to the drug price debate, but the real drag on this healthcare ETF is the 22.69% weight to the healthcare providers industry, meaning this healthcare ETF features significant exposure to the Medicare For All debate. First Trust Health Care AlphaDEX Fund (FXH)Source: Shutterstock Expense ratio: 0.63%Alternatively-weighted, or smart beta, funds have caught on with advisors and investors in recent years, but when it comes to the sector funds in this group, there are often two-fold reminders. When things are going well for that sector, smart beta sector funds can outperform their cap-weighted rivals. When that sector falls out of favor, there is little or no downside protection in alternatively-weighted sector funds.Meet the First Trust Health Care AlphaDEX Fund (NYSEARCA:FXH), a healthcare ETF that has recently been taken to task in significant fashion. This healthcare ETF uses a mix of growth and value traits to build its portfolio, a methodology that can lead to upside when the sector is performing well, but in the current environment, FXH is being hit on multiple fronts.A combined weight of 39.60% to biotechnology and pharmaceuticals stocks exposes FXH to the drug price debate. Second, this healthcare ETF has devotes 17.48% of its weight to healthcare providers, meaning Medicare For All is dinging this fund's performance as well. Put all that together and FXH is experiencing epic April showers with a month-to-date loss of 8.57%.Todd Shriber does not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 High-Yielding Dividend Stocks That Won't Wilt * 4 Energy Stocks Soaring as Trump Tightens on Iran * 7 Tech Stocks With Too Much Risk, Not Enough Upside Compare Brokers The post 3 Healthcare ETFs to Sell Amid Political Headwinds appeared first on InvestorPlace.
The stock market's rebound this year may leave investors wondering if there's any gas left in the tank. CLS Investments offers three 'resilient' ETF ideas.
Big pharmaceutical companies were on the hot seat at Capitol Hill today with CVS Health, Cigna, Prime Therapeutics, Humana, and UnitedHealthcare's OptumRx testifying before the Senate Finance Committee on the rising cost of prescription drugs. Among the topics discussed included rebates paid by drug makers contributing to the high costs and the drug industry's pursuit of profits--all to shift the blame from the pharmaceutical companies to the drug makers. U.S. President Donald Trump has already lambasted the pharmaceutical industry for the rising costs associated with prescription drugs.
Pharmaceutical sector-related ETFs stood out Thursday after Horizon Pharma (HZNP) revealed positive test results for its treatment of thyroid eye disease, or TED. Among the better performing non-leveraged ETFs of Thursday, the First Trust Nasdaq Pharmaceuticals ETF (FTXH) rose 1.8%, Invesco Dynamic Pharmaceuticals ETF (PJP) gained 1.5% and SPDR Pharmaceuticals ETF (XPH) increased 2.3%. Horizon Pharma shares surged 32.5% Thursday following the release of positive test results in its Phase 3 trial of its thyroid eye disease drug, teprotumumab, TheStreet reports.